- Home
- PERI vs RIGL Comparison
PERI vs RIGL Comparison
Compare PERI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERI
- RIGL
- Stock Information
- Founded
- PERI 1999
- RIGL 1996
- Country
- PERI Israel
- RIGL United States
- Employees
- PERI N/A
- RIGL 164
- Industry
- PERI EDP Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PERI Technology
- RIGL Health Care
- Exchange
- PERI Nasdaq
- RIGL Nasdaq
- Market Cap
- PERI 395.5M
- RIGL 334.5M
- IPO Year
- PERI 2006
- RIGL 2000
- Fundamental
- Price
- PERI $9.63
- RIGL $18.90
- Analyst Decision
- PERI Buy
- RIGL Buy
- Analyst Count
- PERI 4
- RIGL 5
- Target Price
- PERI $9.00
- RIGL $36.40
- AVG Volume (30 Days)
- PERI 496.8K
- RIGL 202.3K
- Earning Date
- PERI 05-13-2025
- RIGL 05-06-2025
- Dividend Yield
- PERI N/A
- RIGL N/A
- EPS Growth
- PERI N/A
- RIGL N/A
- EPS
- PERI 0.25
- RIGL 2.08
- Revenue
- PERI $498,286,000.00
- RIGL $203,077,000.00
- Revenue This Year
- PERI N/A
- RIGL $12.53
- Revenue Next Year
- PERI $7.74
- RIGL $15.68
- P/E Ratio
- PERI $36.88
- RIGL $8.76
- Revenue Growth
- PERI N/A
- RIGL 70.16
- 52 Week Low
- PERI $7.00
- RIGL $7.48
- 52 Week High
- PERI $13.49
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- PERI 64.07
- RIGL 52.72
- Support Level
- PERI $8.87
- RIGL $17.89
- Resistance Level
- PERI $9.68
- RIGL $25.42
- Average True Range (ATR)
- PERI 0.38
- RIGL 1.45
- MACD
- PERI 0.05
- RIGL 0.11
- Stochastic Oscillator
- PERI 95.37
- RIGL 27.47
About PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.